First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA
… Disease targeting B4GALT1 Development of Axiomer ® RNA base editing technology platform continues across multiple … against a key Axiomer patent protecting ADAR-mediated RNAediting Well-capitalized with €139 M, in cash and cash …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNAediting technology platform, today announced that Company …
… company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNAediting technology platform, today announced the Annual …
… company dedicated to changing lives through transformative RNA therapies, today announced it has again successfully … filed against a key patent for its ADAR-mediated RNAediting platform Axiomer™. The opposition was filed in …